Dihydromyricetin inhibits melanogenesis in B16F10 melanoma cells.
Dihydromyricetin decreases the expressions of MC1R, MITF and TRP-1.
Dihydromyricetin effectively decreases intracellular ROS and RS levels.
Dihydromyricetin downregulates MAPK, PKA and PKC pathways.